ArticleCureus2024
Psychosis in Laurence-Moon Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psychosis as a rare neuropsychiatric manifestation of Bardet-Biedl syndrome: A case report.The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaurence-Moon syndrome (LMS) is a rare autosomal recessive genetic disorder characterized by a combination of neurological, visual, and endocrine abnormalities. The coexistence of psychiatric disorders in LMS patients can complicate clinical management due to the intricate interplay between neurodevelopmental and psychiatric symptoms. A review of the literature failed to identify a similar case study published in major databases, including PubMed, highlighting the significance of this case report. Understanding these complexities is crucial for improving treatment strategies and patient outcomes. CASE PRESENTATION: A 35-year-old single Saudi male with LMS developed psychiatric symptoms, including social isolation and reduced family interaction since childhood, which worsened over the past two years as his vision deteriorated. The patient also exhibited elevated cholesterol levels and obesity, further complicating his treatment. Two years before seeking psychiatric help, he began experiencing severe auditory hallucinations, believing that his mother engaged in inappropriate activities, which led to increased fear, aggressive behavior, and neglect of basic needs. He was diagnosed with a psychotic disorder related to LMS and was initially treated with aripiprazole at a dose of 20 mg once daily, which significantly improved his symptoms but caused a resting tremor. When the dose was reduced to 10 mg daily, his psychotic symptoms returned, necessitating an increase to 15 mg daily, which stabilized his condition. A trial of escitalopram was ineffective and subsequently discontinued.
conclusionThis case study provides valuable insights into the manifestations and management of psychosis in patients with LMS. A multidisciplinary approach involving psychiatry, neurology, endocrinology, and metabolic care is essential for comprehensive treatment. We recommend genetic testing and counseling for the patient's family, particularly during family planning, with non-invasive prenatal testing (NIPT) for siblings after marriage. Further research is needed to develop targeted treatment strategies and explore the long-term outcomes of psychotropic medications in LMS, aiming to optimize treatment regimens and improve patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.